{"disease":{"id":"non-hodgkin-s-lymphoma-nhl","name":"non hodgkin s lymphoma nhl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01087333","title":"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":1263,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04002947","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06665737","title":"Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Department of Medical Services Ministry of Public Health of Thailand","has_results":false},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05685173","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT02030834","title":"Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT03789240","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07205315","title":"A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT03465540","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Estrella Biopharma, Inc.","has_results":false},{"nct_id":"NCT07059741","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07334574","title":"Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04696705","title":"Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT00923910","title":"Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05144347","title":"Study of XL114 in Subjects With Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT05513612","title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}